TargED Biopharmaceuticals raises EUR 39 Million to bring groundbreaking thrombolytic treatment to patients
Funds will accelerate development of first-in-class targeted thrombolytic treatment into clinical development
28-Feb-2022 -
TargED Biopharmaceuticals, a private biotechnology startup focused on developing improved treatments for thrombotic diseases, announces it has raised Series A financing of EUR 39 million to accelerate development of its lead compound, Microlyse. The financing was led with equal contribution by an ...
acute ischemic stroke
Series A financing
thrombosis
+1